Recent Updates
Recently added Catalysts
MRVI Negative Sentiment Score: 25/100

MARAVAI ALERT: Bragar Eagel & Squire, P.C. is Investigating Maravai LifeSciences Holdings, Inc. on Behalf of Maravai Stockholders and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. is investigating Maravai LifeSciences Holdings, Inc. for potential violations of federal securities laws related to the postponement of its earnings release. The postponement is due to an ongoing assessment of a possible non-cash impairment charge linked to the acquisition of Alphazyme LLC, alongside errors in revenue reporting. Following this news, Maravai's stock price experienced a sharp decline of 21.7%, closing at $3.14 per share, prompting concerns among investors.

Market Sentiment Analysis

CONCERNS & RISKS

  • Maravai is facing a potential investigation regarding violations of federal securities laws.
  • The company postponed its earnings release, indicating possible financial issues.
  • A significant drop in stock price (21.7%) occurred following the announcement of these issues.

Full Press Release Details

NEW YORK , Feb. 27, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ: MRVI) on behalf of Maravai stockholders. Our investigation concerns whether Maravai has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On February 25, 2025, Maravai disclosed that it is postponing its previously announced earnings release and would be unable to timely file its annual financial report. The Company explained it requires additional time to “complete its assessment of a potential non-cash impairment charge related to goodwill associated with its previous acquisition of Alphazyme LLC,” and to “assess an error . . . that resulted in approximately $3.9 million in revenue being recorded in the final week of the second quarter of 2024 upon shipment when it should have been recorded in the first week of the third quarter of 2024 upon receipt by the customer.”
On this news, Maravai’s stock price fell $0.87, or 21.7%, to close at $3.14 per share on February 25, 2025, thereby injuring investors.
If you purchased or otherwise acquired Maravai shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmroe by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Bragar Eagel & Squire

Frequently Asked Questions

What is Bragar Eagel & Squire investigating?

They are investigating potential claims against Maravai LifeSciences for possible violations of securities laws.

Why did Maravai delay its earnings release?

Maravai postponed the release to assess a potential non-cash impairment charge and a revenue recording error.

How did Maravai's stock react to the news?

Maravai's stock price fell by $0.87, or 21.7%, closing at $3.14 per share.

Who should contact Bragar Eagel & Squire?

Investors who purchased Maravai shares and suffered losses should reach out.

Is there a cost to contact Bragar Eagel & Squire?

There is no cost or obligation to contact them regarding these matters.

Last updated: Feb 28, 2025